EU and US could reach trade deal this weekend - Reuters
Investing.com - Truist Securities maintained its buy rating and $48.00 price target on Hinge Health Inc (NYSE:HNGE) following a dinner meeting with company executives on Wednesday. The target sits within the analyst range of $41-$52, with the stock currently trading at $46.49. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
The investment firm hosted Hinge Health’s CFO James Budge and VP of Finance Jeff Hustis as part of its 2025 Truist Securities Healthcare Disrupters & Digital Health Conference, reinforcing its bullish outlook on the digital musculoskeletal care provider.
Truist noted that while Hinge Health shares have risen more than 40% from their IPO price, compared to the S&P’s 5% gain, and investors already anticipate strong second-quarter results, the firm expects business momentum to continue beyond Q2.
The investment bank’s proprietary analysis indicates Hinge Health’s 2026 selling season is off to a promising start, a point Truist had previously highlighted in its initiation report.
Truist identified Hinge Health as its preferred investment in the employer benefits market, citing the company’s strong positioning in the digital musculoskeletal care sector.
In other recent news, Hinge Health has been the focus of several analyst reports following its announcement of HingeSelect, a new network for musculoskeletal care. Truist Securities maintained a buy rating, citing the strategic timing of the network’s launch before the upcoming selling season, with financial impacts expected to materialize in 2027. Raymond (NSE:RYMD) James initiated coverage with an outperform rating, highlighting Hinge Health’s impressive 33% year-over-year revenue growth and robust partner network. Needham also initiated a buy rating, pointing to the company’s market leadership in virtual musculoskeletal care and its significant growth potential. Evercore ISI echoed this optimism, projecting annual growth of about 20% and maintaining a positive outlook on the company’s revenue model and gross margins. William Blair initiated coverage with an outperform rating, emphasizing Hinge Health’s innovative digital platform and its potential to transform patient experiences in musculoskeletal care. These developments underscore Hinge Health’s strong position in the market and the confidence analysts have in its future growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.